|
|
|
| Policy Issues for the Development and Use of Biomarkers in Health |
| Rachael Ritchie, Marie-Ange Baucher |
| Organisation for Economic Co-operation and Development |
|
|
|
Abstract This report describes the scientific, industrial, regulatory, and health care management system context in which biomarkers are being developed. It identifies some of the barriers which may impede biomarker research, discovery, development, commercialisation and, ultimately, uptake in clinics. It also focuses on the use of biomarkers in the health care system, as diagnostics and in medical tests, and explores the use of biomarkers for the development of improved medicines.
|
|
Published: 25 January 2014
|
|
|
|
|
[1] OECD, OECD Health Data 2010, Paris.
[2] World Health Organisation. Preventing Chronic Diseases: a Vital Investment: WHO Global Report, 2005.
[3] Hempel W, Sziraczky G, Swalm L, et, al. Biomarkers: Impact on Biomedical Research and Health Care: Case Reports, OECD Science, Technology and Industry Analytical Paper, Directorate for Science, Technology and Industry, OECD, Paris, 2008.
[4] OECD. Pharmacogenetics: Opportunities and Challenges for Health Innovation, OECD, Paris, 2009b.
[5] Claudio JO, Stewart AK. Advances in Myeloma Genetics and Prospects for Pharmacogenomic Testing in Multiple Myeloma, American Journal of Pharmacogenomics, 2005, 5: 35-43.
[6] McLean LA, Gathmann I, Capdeveile R, et al. Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with Imatinib, Clinical Cancer Research, 2004, 10: 155-165.
[7] Lusky K Wins, Worries on Reimbursement Battlefields, College of American Pathologists, August, 2008.
[8] Genomic Health, Inc. Company Strategy, SWOT Analysis and 5-Year Adjusted Financials, Data Monitor, June, 2006.
[9] Hamilton DP. Genentech's Profit Jumps 64 Percent on Strong Cancer-Drug Sales, Wall Street Journal, January 11, 2006.
[10] Personalized Medicine Coalition. The case for Personalized Medicine, Personalized Medicine Coalition, 2009.
[11] Issa AM. Personalized Medicine and the Practice of Medicine in the 21st Century, McGill Journal of Medicine, 2007, 10(1):53-57.
[12] Epstein RS, Toyer TP, Aubert RE, et al. Warfarin Genotyping Reduces Hospitalisation Rates: Results from the MM-WES (Medco-Mayo Effectiveness Study), Journal of the American College of Cardiology, 2010, 55(25):2804-2812.
[13] Editorial. Vioxx: an unequal partnership between safety and efficacy, The Lancet, 2004, 364 (9442): 1287-1288.
[14] Rubin R. How Did Vioxx Debacle Happen, USA Today, October 12, 2004.
[15] Di Masi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics, 2003, 22:151-185.
[16] Wimo A, Prince M. World Alzheimer Report, Alzheimer's Disease International, Alzheimer's Disease International, 21 September 2010.
[17] OECD. Collaborative Mechanisms for Intellectual Property Management in the Life Sciences, OECD, Paris, 2011.
[18] Centers for Disease Control and Prevention (n.d.). ACCE Model Process for Evaluating Genetic Tests, www.cdc.gov/genomics/gtesting/ACCE/index.htm.
[19] OECD. Health Technologies and Decision Making, OECD, Paris, 2005.
[20] OECD. Guidelines on Human Biobank and Genetic Research Databases, OECD, Paris, 2009a.
[21] Novelli G. Genetic tests and genomic biomarkers: regulation, qualification and validation. Clinical Cases, 2008, 5:140-154.
[22] Personalised Medicine Coalition. The Adverse Impact of the US Reimbursement System on the Development and Adoption of Personalised Medicine Diagnostics, Personalised Medicine Coalition, 2010.
[23] Health Advances. The reimbursement Landscape for novel diagnostics, 2010. http://www.bio.org/healthcare/personalized/Health_Advances&BIO_Novel_Diagnostics_Reimburs_20110103.pdf.
[24] Schmid EF, Smith DA. Is declining innovation in the pharmaceutical industry a myth? Drug Discovery Today, 2005, 10: 1031-1039.
[25] Peck RW. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. Drug Discovery Today, 2007, 12:289-294.
[26] Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase Ⅲ, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Clin Oncol. 2011, 20;29(21):2866-2874.
[27] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 3;361(10):947-957. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
